Company Filing History:
Years Active: 2020-2024
Title: Jan Stefan Persson Grudén: Innovator in Obesity Treatment
Introduction
Jan Stefan Persson Grudén is a notable inventor based in Uppsala, Sweden. He has made significant contributions to the field of pharmaceuticals, particularly in the treatment of obesity and related metabolic disorders. With a total of 2 patents to his name, Grudén's work is recognized for its innovative approach to drug formulation.
Latest Patents
Grudén's latest patents focus on a modified-release composition of orlistat and acarbose. This composition is designed for the treatment of obesity and related metabolic disorders. The invention comprises individually distinct parts with different release patterns. The first part, G1, includes from about 5 to about 70% w/w of the total dose of acarbose. The second part, G2A, comprises from about 30 to about 95% w/w of the total dose of acarbose. The third part, G2B, contains from about 10 to about 90% w/w of the total dose of orlistat. Lastly, the fourth part, G3, includes from about 10 to about 80% w/w of the total dose of orlistat. The total concentration of acarbose and orlistat in the composition is 100% w/w.
Career Highlights
Grudén is currently associated with Empros Pharma AB, where he continues to develop innovative pharmaceutical solutions. His work has been instrumental in advancing treatments for obesity, a growing health concern worldwide.
Collaborations
Throughout his career, Grudén has collaborated with notable colleagues such as Göran Alderborn and Anders Forslund. These collaborations have contributed to the success of his innovative projects and patents.
Conclusion
Jan Stefan Persson Grudén is a prominent figure in the pharmaceutical industry, particularly in the development of treatments for obesity. His innovative patents and collaborations highlight his commitment to advancing healthcare solutions.